# US 11,433,067 B2 · Bupropion as a modulator of drug activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,067 B2
- Document ID: US11433067B2
- Status: Granted
- Kind: B2
- Application number: 17/547,050
- Filed: 2021-12-09
- Published: 2022-03-31
- Granted: 2022-09-06
- Earliest claimed: 2013-11-05
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US11433067B2

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/381: having five-membered rings
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

## Claims

### Claim 1

A dosage form comprising:
about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and
about 40 mg to about 60 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; and
wherein the dextromethorphan and the bupropion are substantially uniformly dispersed within the dosage form.

### Claim 2 (depends on 1)

The dosage form of claim 1, comprising about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide.

### Claim 3 (depends on 1)

The dosage form of claim 1, wherein the bupropion is formulated for sustained release.

### Claim 4 (depends on 1)

A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 1 to a human being.

### Claim 5 (depends on 4)

The method of claim 4, wherein the dosage form is administered orally.

### Claim 6 (depends on 4)

The method of claim 4, wherein the dosage form is administered once daily.

### Claim 7 (depends on 4)

The method of claim 4, wherein the dosage form is administered twice daily.

### Claim 8 (depends on 4)

The method of claim 4, wherein the dosage form is administered to the human being for at least 8 consecutive days.

### Claim 9 (depends on 4)

The method of claim 4, wherein the dosage form is administered to the human being for at least 14 consecutive days.

### Claim 10 (depends on 4)

The method of claim 4, wherein the dosage form is administered to the human being for at least 30 consecutive days.

### Claim 11

A dosage form comprising:
about 200 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and
about 80 mg to about 100 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; and
wherein the dextromethorphan and the bupropion are substantially uniformly dispersed within the dosage form.

### Claim 12 (depends on 11)

The dosage form of claim 11, comprising about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide.

### Claim 13 (depends on 11)

The dosage form of claim 11, wherein the bupropion is formulated for sustained release.

### Claim 14 (depends on 11)

A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 11 to a human being.

### Claim 15 (depends on 14)

The method of claim 14, wherein the dosage form is administered orally.

### Claim 16 (depends on 14)

The method of claim 14, wherein the dosage form is administered once daily.

### Claim 17 (depends on 14)

The method of claim 14, wherein the dosage form is administered to the human being for at least 8 consecutive days.

### Claim 18 (depends on 14)

The method of claim 14, wherein the dosage form is administered to the human being for at least 14 consecutive days.

### Claim 19 (depends on 14)

The method of claim 14, wherein the dosage form is administered to the human being for at least 30 consecutive days.